Oslo, Norway and BILTHOVEN, Netherlands, October 6, 2022 /PRNewswire/ — CEPI, the Coalition for Epidemic Preparedness Innovations, and Dutch vaccine clinical development and manufacturing organization Intravacc, today announced CEPI’s latest funding commitment to advance the development of vaccines that provide comprehensive protection against SARS -CoV-2 offer (including its variants) and others betacoronaviruses.
CEPI provides start-up financing of up to $4.8 million to Intravacc – a global leader in translational research and development of preventive and therapeutic vaccines – to advance the development of a comprehensively protective vaccine betacoronavirus Vaccine candidate that can be administered intranasally.
The CEPI funds will support the pre-clinical development and testing of Intravacc’s subunit vaccine candidate (Avacc 101) based on its outer membrane vesicle (OMV) platform.
This technology has the potential to be rapidly adapted to combat disease outbreaks caused by disease emergence betacoronavirus Strains and variants as well as to protect against pre-emergence betacoronaviruses (i.e. before they “spill over” from animals to infect humans). In particular, the vaccine candidate Avacc 101 is said to offer comprehensive protection against SARS-CoV-1, SAR-CoV-2 and MERS-CoV. This platform will enable the presentation of universal spike molecules and will contain ‘epitopes’ that can also elicit T-cell responses.
Unlike the COVID-19 vaccines currently in use, this candidate is administered intranasally. This method of administration could help create the mucosal immunity needed to block viral infection, thereby reducing person-to-person transmission.
Allow equal access
CEPI is committed to the principle of equal access to the vaccines it finances. Under the terms of the Funding Agreement, Intravacc has committed to achieving equitable access to the results of this project in accordance with CEPI Equal Access Policy.
DR Richard HatchettCEO of CEPI said:
“The latest waves…
